Should I buy or sell Genenta Science stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Genenta Science in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" GNTA shares. View GNTA analyst ratings or view top-rated stocks .

How have GNTA shares performed in 2024?

Genenta Science's stock was trading at $4.95 at the beginning of 2024. Since then, GNTA shares have decreased by 32.3% and is now trading at $3.35. View the best growth stocks for 2024 here .

Are investors shorting Genenta Science?

Genenta Science saw a drop in short interest in the month of March. As of March 31st, there was short interest totaling 3,000 shares, a drop of 9.1% from the March 15th total of 3,300 shares. Based on an average daily trading volume, of 4,300 shares, the short-interest ratio is presently 0.7 days. View Genenta Science's Short Interest .

When is Genenta Science's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 24th 2024. View our GNTA earnings forecast .

When did Genenta Science IPO?

Genenta Science (GNTA) raised $28 million in an IPO on Wednesday, December 15th 2021. The company issued 2,400,000 shares at $10.50-$12.50 per share.

How do I buy shares of Genenta Science?

Shares of GNTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:GNTA

Genenta Science (GNTA) Stock Price, News & Analysis

→ [Urgent!] Generational Wealth Gameplan (From Crypto 101 Media) (Ad)

Free GNTA Stock Alerts

$3.69

+0.69 (+23.00%)

(As of 12:36 PM ET)

Compare

Today's Range: $3.15
▼
$3.70
50-Day Range: $3.14
▼
$4.49
52-Week Range: $3.00
▼
$6.81

Volume: 3,679 shs
Average Volume: 4,509 shs
Market Capitalization: $67.23 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Get Genenta Science alerts:

Ad Crypto 101 Media

[Urgent!] Generational Wealth Gameplan

A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.

Click here to get instant access to the guide

About Genenta Science Stock (NASDAQ:GNTA)

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is also developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. In addition, it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. The company was incorporated in 2014 and is headquartered in Milan, Italy.

GNTA Stock Price History

30 days | 90 days | 365 days | Advanced Chart

GNTA Stock News Headlines

April 11, 2024 | cnn.com

Genenta Science SpA Sponsored ADR

March 4, 2024 | msn.com

BioVie stock plunges 43% following public offering pricing

April 18, 2024 | Crypto Swap Profits (Ad)

Did You Get Your Free Bitcoin Yet?

And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.

February 10, 2024 | markets.businessinsider.com

Buy Rating for Genenta Science SpA on Strong Clinical Prospects and Innovative Gene Therapy Platform

February 8, 2024 | finance.yahoo.com

Genenta Demonstrated Reprogramming of the Tumor Microenvironment in GBM Patients, Paving the Way for Innovative Treatments of Solid Tumors

February 3, 2024 | finance.yahoo.com

Is Genenta Science (NASDAQ:GNTA) In A Good Position To Invest In Growth?

November 14, 2023 | finance.yahoo.com

Individual investors account for 54% of Genenta Science S.p.A.'s (NASDAQ:GNTA) ownership, while insiders account for 30%

August 18, 2023 | au.finance.yahoo.com

Genenta Science S.p.A. (GNTA)

April 18, 2024 | Crypto Swap Profits (Ad)

Did You Get Your Free Bitcoin Yet?

July 28, 2023 | finance.yahoo.com

Genenta Announces Ongoing Clinical Trial Progress and Proposed Expansion in Solid Tumor Treatments

July 8, 2023 | finance.yahoo.com

Here's Why We're Not Too Worried About Genenta Science's (NASDAQ:GNTA) Cash Burn Situation

June 29, 2023 | finanznachrichten.de

GENENTA SCIENCE SPA: The European Commission Grants Orphan Drug Designation to Temferon for Treatment of Glioma

June 29, 2023 | finance.yahoo.com

The European Commission Grants Orphan Drug Designation to Temferon™ for Treatment of Glioma

May 17, 2023 | finance.yahoo.com

Insiders own 30% of Genenta Science S.p.A. (NASDAQ:GNTA) shares but individual investors control 59% of the company

May 16, 2023 | finance.yahoo.com

Genenta to Provide Update on Lead Product Temferon™

April 26, 2023 | finanznachrichten.de

GENENTA SCIENCE SPA: Genenta Announces Fiscal Year 2022 Financial Results and Annual Report on Form 20-F Filing

April 26, 2023 | finance.yahoo.com

Genenta Announces Fiscal Year 2022 Financial Results and Annual Report on Form 20-F Filing

April 3, 2023 | finance.yahoo.com

Genenta Announces Extension of License Agreement with Ospedale San Raffaele to All Solid Tumor Indications

March 2, 2023 | marketwatch.com

Genenta Gets FDA Orphan-Drug Designation for Temferon in Glioblastoma Multiforme >GNTA

March 2, 2023 | finance.yahoo.com

FDA Grants Orphan Drug Designation to Temferon for Treatment of Glioblastoma Multiforme

February 24, 2023 | wsj.com

Genenta Science S.p.A. ADR

February 8, 2023 | markets.businessinsider.com

H.C. Wainwright Keeps Their Buy Rating on Genenta Science SpA Sponsored ADR (GNTA)

February 7, 2023 | finance.yahoo.com

Genenta Science and AGC Biologics Enter Development and Manufacturing Service Agreement

January 29, 2023 | finance.yahoo.com

We Think Genenta Science (NASDAQ:GNTA) Can Easily Afford To Drive Business Growth

December 8, 2022 | finance.yahoo.com

Genenta Science S.p.A. (NASDAQ:GNTA) most popular amongst individual investors who own 60%, insiders hold 29%

November 7, 2022 | finance.yahoo.com

Genenta Update at SITC22 Indicates Potential for Anti-Tumor Immune System Reset after Temferon™ Treatment in Glioblastoma Patients

October 24, 2022 | finance.yahoo.com

Genenta Provides First Half 2022 Business Update and Financial Results

See More Headlines

Receive GNTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Genenta Science and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today: 4/18/2024
Next Earnings (Estimated): 4/24/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:GNTA
CUSIP: N/A
CIK: 1838716
Web: www.genenta.com
Phone: 39-02-2643-4681
Fax: N/A
Employees: 14
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 12.25
Quick Ratio: 12.25

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.21 per share
Price / Book: 3.05

Miscellaneous

Outstanding Shares: 18,220,000
Free Float: 12,936,000
Market Cap: $67.23 million
Optionable: Not Optionable
Beta: 0.72

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

Mr. Pierluigi Paracchi (Age 51)
Vice Chairman of the Board, CEO & GM
Dr. Luigi Naldini M.D. (Age 65)
Ph.D., Co-Founder & Chairman of the Executive Scientific Board
Dr. Bernard Rudolph Gentner M.D. (Age 49)
Ph.D., Co-Founder & Member of the Executive Scientific Board
Mr. Richard B. Slansky (Age 66)
Chief Financial Officer
Dr. Carlo Russo M.D. (Age 71)
Chief Medical Officer & Head of Development
Dr. Stefania Mazzoleni Ph.D. (Age 42)
Director of Program Development
Ms. Barbara Regonini (Age 51)
Director of Finance

Key Competitors

View All Competitors

GNTA Stock Analysis - Frequently Asked Questions

Should I buy or sell Genenta Science stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Genenta Science in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" GNTA shares.
View GNTA analyst ratings or view top-rated stocks.
How have GNTA shares performed in 2024?: Genenta Science's stock was trading at $4.95 at the beginning of 2024. Since then, GNTA shares have decreased by 32.3% and is now trading at $3.35.
View the best growth stocks for 2024 here.
Are investors shorting Genenta Science?: Genenta Science saw a drop in short interest in the month of March. As of March 31st, there was short interest totaling 3,000 shares, a drop of 9.1% from the March 15th total of 3,300 shares. Based on an average daily trading volume, of 4,300 shares, the short-interest ratio is presently 0.7 days.
View Genenta Science's Short Interest.
When is Genenta Science's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 24th 2024.
View our GNTA earnings forecast.

When did Genenta Science IPO?: Genenta Science (GNTA) raised $28 million in an IPO on Wednesday, December 15th 2021. The company issued 2,400,000 shares at $10.50-$12.50 per share.
How do I buy shares of Genenta Science?: Shares of GNTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:GNTA) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial